ADX10059 Migraine Prevention Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2010

Conditions
Migraine
Interventions
DRUG

ADX10059

oral administration

DRUG

ADX10059

Oral administration

DRUG

ADX10059

Oral administration

DRUG

ADX10059 Matching Placebo

Oral administration

Trial Locations (31)

Unknown

Vienna

Liège, Liège

Sint-Truiden, Sint-Truiden

Wilrijk, Wilrijk

Lille, Lille

Nice, Nice

Paris, Paris

Toulouse, Toulouse

06, Berlin

Berlin Hellersdorf 11, Berlin

Bochum, Bochum

Dreseden, Dresden

02, Essen

28, Essen

Frankfurt, Frankfurt

Freiburg, Freiburg im Breisgau

Göppingen, Göppingen

Görlitz, Görlitz

Hamburg, Hamburg

Itzehoe, Itzehoe

Leipzig, Leipzig

Magdeburg, Magdeburg

05, München

10, München

Münster, Münster

Wiesbaden, Wiesbaden

Berkshire, Berkshire

Cardiff, Cardiff

Liverpool, Liverpool

24, London

Manchester, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Addex Pharma S.A.

INDUSTRY

NCT00820105 - ADX10059 Migraine Prevention Study | Biotech Hunter | Biotech Hunter